Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Type 2 diabetes is a form of diabetes characterized ... is rising and decreases the production of glucose in the liver: Januvia (sitagliptin) Onglyza (saxagliptin) Tradjenta (lingliptin) Nesina ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

Delhi HC verdict on Januvia boost for Glenmark ... Sun Pharmaceutical Industries is in pact with MSD to co-market diabetes drugs in India, reports CNBC-TV18. It touched an intraday high of ...